Investigational drug · Phase 3
SAL003
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia, Hyperlipidemias.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
3
Any phase or sponsor naming "SAL003"
First trial start
2023
Oct 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAL003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
- Hyperlipidemias
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SAL003" as an intervention, largest first.
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07253584 · 720 participants · Start Dec 19, 2023 · Primary completion Jun 23, 2025
Drug: SAL003 140 mg; Placebo · For: Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
Sites: Xi’an, China
- A Study of SAL003 in Participants With Hypercholesterolemia and Mixed DyslipidemiaPivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07295418 · 618 participants · Start Oct 23, 2023 · Primary completion Apr 22, 2025
Drug: SAL003 140 mg; Placebo · For: Hyperlipidemias
Sites: Beijing, China
- A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed DyslipidemiaPivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07278830 · 214 participants · Start Jun 2, 2023 · Primary completion May 24, 2024
Drug: SAL003 140mg+Atorvastatin; SAL003 420mg+Atorvastatin and 2 more · For: Hypercholesterolemia and Mixed Dyslipidemia
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- The Integrated Stress Response Pathway Improves Aged Murine Muscle Stem Cell Activation and in vivo Regeneration.
Brown AD, Scaramozza A, Zhang H, et al. · bioRxiv 2025
- Targeting Endoplasmic Reticulum Stress by Natural and Chemical Compounds Ameliorates Cisplatin-Induced Nephrotoxicity: A Review.
Mashayekhi-Sardoo H, Rezaee R, Yarmohammadi F, et al. · Biol Trace Elem Res 2025
- Model-Informed Dose Selection for a Novel Human Immunoglobulin G4 Derived Monoclonal Antibody Targeting Proprotein Convertase Kwashiorkor Type 9: Insights from Population Pharmacokinetics-Pharmacodynamics and Systems Pharmacology.
Peng J, Huang J, Tan H, et al. · ACS Pharmacol Transl Sci 2024
- Sal003 alleviated intervertebral disc degeneration by inhibiting apoptosis and extracellular matrix degradation through suppressing endoplasmic reticulum stress pathway in rats.
Chen Y, Li B, Xu Y, et al. · Front Pharmacol 2023
- Integrated Stress Response Regulation of Corneal Epithelial Cell Motility and Cytokine Production.
Chu HS, Peterson C, Chamling X, et al. · Invest Ophthalmol Vis Sci 2022
- Induction of the integrated stress response in the rat cornea.
Peterson C, Kim YC, Ensign LM, et al. · Exp Eye Res 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.